[1] |
STEINMAN J B, SALOMAO M A, PAJVANI U B. Zonation in NASH——a key paradigm for understanding pathophysiology and clinical outcomes[J]. Liver Int, 2021, 41(11):2534-2546. DOI: 10.1111/liv.15025.
|
[2] |
SEMMLER G, DATZ C, REIBERGER T,et al. Diet and exercise in NAFLD/NASH:beyond the obvious[J]. Liver Int, 2021, 41(10):2249-2268. DOI: 10.1111/liv.15024.
|
[3] |
VARGHESE D S, ALI B R. Pathological crosstalk between oxidized LDL and ER stress in human diseases:a comprehensive review[J]. Front Cell Dev Biol, 2021, 9:674103. DOI: 10.3389/fcell.2021.674103.
|
[4] |
刘君,杨艳君,韩伟. 尿微量白蛋白与尿肌酐比值对2型糖尿病合并非酒精性脂肪肝的影响[J]. 安徽医药,2021,25(8):1656-1659.
|
[5] |
DE OLIVEIRA DOS SANTOS A R, DE OLIVEIRA ZANUSO B, MIOLA V F B,et al. Adipokines,myokines,and hepatokines:crosstalk and metabolic repercussions[J]. Int J Mol Sci, 2021, 22(5):2639. DOI: 10.3390/ijms22052639.
|
[6] |
EZER S, BAYÉS M, OUTIELOMAA O,et al. Ectodysplasin is a collagenous trimeric typeⅡmembrane protein with a tumor necrosis factor-like domain and co-localizes with cytoskeletal structures at lateral and apical surfaces of cells[J]. Hum Mol Genet, 1999, 8(11):2079-2086. DOI: 10.1093/hmg/8.11.2079.
|
[7] |
CHEN Y, MOLLOY S S, THOMAS L,et al. Mutations within a furin consensus sequence block proteolytic release of ectodysplasin-A and cause X-linked hypohidrotic ectodermal dysplasia[J]. PNAS, 2001, 98(13):7218-7223. DOI: 10.1073/pnas.131076098.
|
[8] |
NIKOPENSIUS T, ANNILO T, JAGOMÄGI T,et al. Non-syndromic tooth agenesis associated with a nonsense mutation in ectodysplasin-A(EDA)[J]. J Dent Res, 2013, 92(6):507-511. DOI: 10.1177/0022034513487210.
|
[9] |
AWAZAWA M, GABEL P, TSAOUSIDOU E,et al. A microRNA screen reveals that elevated hepatic ectodysplasin A expression contributes to obesity-induced insulin resistance in skeletal muscle[J]. Nat Med, 2017, 23(12):1466-1473. DOI: 10.1038/nm.4420.
|
[10] |
American Diabetes Association. Diagnosis and classification of diabetes mellitus[J]. Diabetes Care, 2014, 37(Suppl 1):S81-90. DOI: 10.2337/dc14-s081.
|
[11] |
|
[12] |
JUNG T W, YOO H J, CHOI K M. Implication of hepatokines in metabolic disorders and cardiovascular diseases[J]. BBA Clin, 2016, 5:108-113. DOI: 10.1016/j.bbacli.2016.03.002.
|
[13] |
HUANG R L, LI C H, DU Y F,et al. Discovery of a role of the novel hepatokine,hepassocin,in obesity[J]. Biofactors, 2020, 46(1):100-105. DOI: 10.1002/biof.1574.
|
[14] |
ENNEQUIN G, SIRVENT P, WHITHAM M. Role of exercise-induced hepatokines in metabolic disorders[J]. Am J Physiol Endocrinol Metab, 2019, 317(1):E11-24. DOI: 10.1152/ajpendo.00433.2018.
|
[15] |
MISU H. Identification of hepatokines involved in pathology of type 2 diabetes and obesity[J]. Endocr J, 2019, 66(8):659-662. DOI: 10.1507/endocrj.EJ19-0255.
|
[16] |
|
[17] |
NAGASHIMADA M, HONDA M. Effect of microbiome on non-alcoholic fatty liver disease and the role of probiotics,prebiotics,and biogenics[J]. Int J Mol Sci, 2021, 22(15):8008. DOI: 10.3390/ijms22158008.
|
[18] |
WATT M J, MIOTTO P M, DE NARDO W,et al. The liver as an endocrine organ-linking NAFLD and insulin resistance[J]. Endocr Rev, 2019, 40(5):1367-1393. DOI: 10.1210/er.2019-00034.
|
[19] |
LI Y, SU X, ROHATGI N,et al. Hepatic lipids promote liver metastasis[J]. JCI Insight, 2020, 5(17):136215. DOI: 10.1172/jci.insight.136215.
|
[20] |
|
[21] |
FUCHS C D, RADUN R, DIXON E D,et al. Hepatocyte-specific deletion of adipose triglyceride lipase(adipose triglyceride lipase/patatin-like phospholipase domain containing 2)ameliorates dietary induced steatohepatitis in mice[J]. Hepatology, 2022, 75(1):125-139. DOI: 10.1002/hep.32112.
|
[22] |
YANG J, ZHOU W J, ZHU J Z,et al. Circulating ectodysplasin A is a potential biomarker for nonalcoholic fatty liver disease[J]. Clin Chim Acta, 2019, 499:134-141. DOI: 10.1016/j.cca.2019.09.009.
|
[23] |
BAYLISS J, OOI G J, DE NARDO W,et al. Ectodysplasin A is increased in non-alcoholic fatty liver disease,but is not associated with type 2 diabetes[J]. Front Endocrinol:Lausanne, 2021, 12:642432. DOI: 10.3389/fendo.2021.642432.
|
[24] |
CARDOSO A L, FERNANDES A, AGUILAR-PIMENTEL J A,et al. Towards frailty biomarkers:candidates from genes and pathways regulated in aging and age-related diseases[J]. Ageing Res Rev, 2018, 47:214-277. DOI: 10.1016/j.arr.2018.07.004.
|